
Results
2
Large Cap Companies that analysts expect to have high earnings, revenue or cash flow growth in the next 3 years.
2 companies
argenx
Market Cap: €43.4b
A commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally.
ARGX
€709.00
7D
-1.3%
1Y
14.5%
UCB
Market Cap: €50.3b
A biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide.
UCB
€265.00
7D
1.5%
1Y
39.9%